Helen Griffiths

Dr. Helen Griffiths


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2019 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
HGHelen Griffiths
Helen Griffiths
FDFiona Duffy
Fiona Duffy
LDLouise Duffy
Louise Duffy
SBSarah Brown
Sarah Brown
HHHarriet Hockaday
Harriet Hockaday
MSMatthias Schwannauer
Matthias Schwannauer
Background: Mentalization Based Therapy (MBT) has yielded promising outcomes for reducing self-harm, although to date only one study has reported MBT’s effectiveness for adolescents (Rossouw and Fonagy, J Am Acad Child Adolesc Psychiatry 51:1304–1313, 2012) wherein the treatment protocol consisted of an intensive programme of individual and family therapy. We sought to investigate an adaptation of the adult MBT introductory manual in a group format for adolescents. Methods: The present study is a randomised controlled single blind feasibility trial that aims to (1) adapt the original explicit MBT introductory group manual for an adolescent population (MBT-Ai) and to (2) assess the feasibility of a trial of MBT-Ai through examination of consent rates, attendance, attrition and self-harm. Repeated measures ANOVAs were conducted to examine change over time in independent and dependent variables between groups, and multi level models (MLM) were conducted to examine key predictors in relation to change over time with self-report self-harm and emergency department presentation for harm as the primary outcome variables. Results: Fifty-three young people consented to participate and were randomised to MBT-Ai + TAU or TAU alone. Five participants withdrew from the trial. Trial procedures seemed appropriate and safe, with acceptable group attendance. Self-reported self-harm and emergency department presentation for self-harm significantly decreased over time in both groups, though there were no between group differences. Social anxiety, emotion regulation, and borderline traits also significantly decreased over time in both groups. Mentalization emerged as a significant predictor of change over time in self reported self harm and hospital presentation for self-harm. Conclusions: It was feasible to carry out an RCT of MBT-Ai for adolescents already attending NHS CAMHS who have recently self-harmed. Our data gave signals that suggested a relatively brief group-based MBT-Ai intervention may be a promising intervention with potential for service implementation. Future research should consider the appropriate format, dosage and intensity of MBT for the adolescent population. Trial registration: NCT02771691; Trial Registration Date: 25/04/2016.

30 March 2023 in Journal of Social Distress and Homelessness
Verified
Journal Article
Open access
ALAliénor H. Lemieux-Cumberlege
Aliénor H. Lemieux-Cumberlege
HGHelen Griffiths
Helen Griffiths
EPEmily Pathe
Emily Pathe
ABAdam Burley
Adam Burley
People experiencing homelessness (PEH) frequently have multiple and complex needs that may contribute to interpersonal difficulties that affect their relationships with services. As a result, professionals working in frontline homelessness services are frequently exposed to primary trauma (e.g. workplace aggression, crisis situations) and secondary trauma (e.g. hearing about service users’ traumatic experiences). This cross-sectional study explored organizational and individual factors in relation to three related but distinct facets of work-related distress: posttraumatic stress disorder (PTSD), secondary traumatic stress (STS), and burnout. A sample of 139 frontline workers in UK homelessness services completed an inventory of 15 possible distressing workplace experiences and four psychometric questionnaires. Results clearly evidence that frontline workers are exposed to high levels of potentially traumatic incidents at work and that this is associated with significant distress, with 23% of the sample meeting the threshold for PTSD diagnosis. Hierarchical multiple regression analyses identified trauma exposure and the use of “maladaptive” cognitive coping strategies as strong predictors of PTSD and STS, while organizational culture and compassion satisfaction were protective against burnout. These findings have important service implications, and recommendations are made regarding trauma- and psychologically informed approaches that organizations can implement to effectively support their employees.

1 February 2019 in Health Technology Assessment
Verified
Journal Article
Closed access
AMAnthony P Morrison
Anthony P Morrison
MPMelissa Pyle
Melissa Pyle
AGAndrew Gumley
Andrew Gumley
MSMatthias Schwannauer
Matthias Schwannauer
DTDouglas Turkington
Douglas Turkington
BTBarnes TRE
Barnes TRE
Background: Clozapine (clozaril, Mylan Products Ltd) is a first-choice treatment for people with schizophrenia who have a poor response to standard antipsychotic medication. However, a significant number of patients who trial clozapine have an inadequate response and experience persistent symptoms, called clozapine-resistant schizophrenia (CRS). There is little evidence regarding the clinical effectiveness of pharmacological or psychological interventions for this population.Objectives: To evaluate the clinical effectiveness and cost-effectiveness of cognitive–behavioural therapy (CBT) for people with CRS and to identify factors predicting outcome.Design: The Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial was a parallel-group, randomised, outcome-blinded evaluation trial. Randomisation was undertaken using permuted blocks of random size via a web-based platform. Data were analysed on an intention-to-treat (ITT) basis, using random-effects regression adjusted for site, age, sex and baseline symptoms. Cost-effectiveness analyses were carried out to determine whether or not CBT was associated with a greater number of quality-adjusted life-years (QALYs) and higher costs than treatment as usual (TAU).Setting: Secondary care mental health services in five cities in the UK.Participants: People with CRS aged ≥ 16 years, with anInternational Classification of Diseases, Tenth Revision (ICD-10) schizophrenia spectrum diagnoses and who are experiencing psychotic symptoms.Interventions: Individual CBT included up to 30 hours of therapy delivered over 9 months. The comparator was TAU, which included care co-ordination from secondary care mental health services.Main outcome measures: The primary outcome was the Positive and Negative Syndrome Scale (PANSS) total score at 21 months and the primary secondary outcome was PANSS total score at the end of treatment (9 months post randomisation). The health benefit measure for the economic evaluation was the QALY, estimated from the EuroQol-5 Dimensions, five-level version (EQ-5D-5L), health status measure. Service use was measured to estimate costs.Results: Participants were allocated to CBT (n = 242) or TAU (n = 245). There was no significant difference between groups on the prespecified primary outcome [PANSS total score at 21 months was 0.89 points lower in the CBT arm than in the TAU arm, 95% confidence interval (CI) –3.32 to 1.55 points;p = 0.475], although PANSS total score at the end of treatment (9 months) was significantly lower in the CBT arm (–2.40 points, 95% CI –4.79 to –0.02 points;p = 0.049). CBT was associated with a net cost of £5378 (95% CI –£13,010 to £23,766) and a net QALY gain of 0.052 (95% CI 0.003 to 0.103 QALYs) compared with TAU. The cost-effectiveness acceptability analysis indicated a low likelihood that CBT was cost-effective, in the primary and sensitivity analyses (probability < 50%). In the CBT arm, 107 participants reported at least one adverse event (AE), whereas 104 participants in the TAU arm reported at least one AE (odds ratio 1.09, 95% CI 0.81 to 1.46;p = 0.58).Conclusions: Cognitive–behavioural therapy for CRS was not superior to TAU on the primary outcome of total PANSS symptoms at 21 months, but was superior on total PANSS symptoms at 9 months (end of treatment). CBT was not found to be cost-effective in comparison with TAU. There was no suggestion that the addition of CBT to TAU caused adverse effects. Future work could investigate whether or not specific therapeutic techniques of CBT have value for some CRS individuals, how to identify those who may benefit and how to ensure that effects on symptoms can be sustained.Trial registration: Current Controlled Trials ISRCTN99672552.Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full inHealth Technology Assessment; Vol. 23, No. 7. See the NIHR Journals Library website for further project information.

20 July 2016 in Child and Adolescent Mental Health
Verified
Journal Article
Closed access
PDF file
HGHelen Griffiths
Helen Griffiths
ANAbbi Noble
Abbi Noble
FDFiona Duffy
Fiona Duffy
MSMatthias Schwannauer
Matthias Schwannauer

5 August 2016 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
MPMelissa Pyle
Melissa Pyle
JNJohn Norrie
John Norrie
MSMatthias Schwannauer
Matthias Schwannauer
DKDavid Kingdon
David Kingdon
AGAndrew Gumley
Andrew Gumley
AMAnthony P. Morrison
Anthony P. Morrison
For around a third of people with a diagnosis of schizophrenia, the condition proves to respond poorly to treatment with many typical and atypical antipsychotics. This is commonly referred to as treatment-resistant schizophrenia. Clozapine is the only antipsychotic with convincing efficacy for people whose symptoms are considered treatment-resistant to antipsychotic medication. However, 30–40 % of such conditions will have an insufficient response to the drug. Cognitive behavioural therapy has been shown to be an effective treatment for schizophrenia when delivered in combination with antipsychotic medication, with several meta-analyses showing robust support for this approach. However, the evidence for the effectiveness of cognitive behavioural therapy for people with a schizophrenia diagnosis whose symptoms are treatment-resistant to antipsychotic medication is limited. There is a clinical and economic need to evaluate treatments to improve outcomes for people with such conditions. A parallel group, prospective randomised, open, blinded evaluation of outcomes design will be used to compare a standardised cognitive behavioural therapy intervention added to treatment as usual versus treatment as usual alone (the comparator group) for individuals with a diagnosis of schizophrenia for whom an adequate trial of clozapine has either not been possible due to tolerability problems or was not associated with a sufficient therapeutic response. The trial will be conducted across five sites in the United Kingdom. The recruitment target of 485 was achieved, with a final recruitment total of 487. This trial is the largest definitive, pragmatic clinical and cost-effectiveness trial of cognitive behavioural therapy for people with schizophrenia whose symptoms have failed to show an adequate response to clozapine treatment. Using a prognostic risk model, baseline information will be used to explore whether there are identifiable subgroups for which the treatment effect is greatest. Current Controlled Trials ISRCTN99672552 . Registered 29th November 2012.

19 March 2025 in Journal of Clinical Psychology
Verified
Journal Article
Open access
EOErcan Ozdemir
Ercan Ozdemir
ZXZhuoni Xiao
Zhuoni Xiao
HGHelen Griffiths
Helen Griffiths
AMAngus MacBeth
Angus MacBeth
Aims: Disturbances involving impairments in experience and expression of affect are frequently identified in schizophrenia samples. Alexithymia underlies cognitive impairments in identification and expression of affect, further implicated in affect dysregulation. The current review aimed to systematically review the literature and estimate the strength of associations between alexithymia and schizophrenia phenomenology.Method: A systematic review and meta‐analysis identified 67 studies involving measures of alexithymia in psychosis. All studies were assessed for quality and publication bias. Overall, data from 47 studies were suitable for meta‐analysis.Results: Alexithymia and schizophrenia were consistently positively associated with a large effect size (k = 11). Compared to control groups, a schizophrenia diagnosis was positively associated with large magnitude effects for difficulties in identifying feelings (k = 18) and moderate effect sizes for difficulties in describing feelings (k = 17) and externally oriented thinking (k = 11). Data from community samples indicated moderate associations between subclinical negative symptoms and difficulties in identifying and describing feelings (k = 4) and a small association between positive symptoms and difficulties in identifying feelings (k = 5).Conclusions: Alexithymia and schizophrenia are strongly associated. However, methodological issues limit the establishment of directionality in these associations. The majority of studies use cross‐sectional designs reliant on self‐report assessments which may result in over‐estimation of the reported effect sizes. Future research could conceptualize alexithymia as a stress‐reactive multidimensional construct, and modeling dynamic relationships between alexithymia, psychological distress, and schizophrenia phenomenology should incorporate confounders such as gender, age, and neurocognition.